Microbubble Drug Delivery
Microbubble Drug Delivery - Related Videos
14:10
Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation
0 Views •
Cited by 15 •
2010
Insonation of microbubbles is a promising strategy for tumor ablation at reduced time-averaged acoustic powers, as well as for the targeted delivery of therapeutics. The purpose of the present study is to develop low duty cycle ultrasound pulsing strategies and nanocarriers to maximize non-thermal microvascular ablation and payload delivery to subcutaneous C6 gliomas.
06:10
Injection of Microbubbles into Isolated Mouse Embryos: A Technique to Deliver Microbubble Contrast Agents into the Vasculature of Living Murine Embryos
0 Views •
2025
This video demonstrates a procedure to inject microbubble contrast agents into an isolated late gestation stage mouse embryo. The microbubble contrast agent-based ultrasound imaging helps visualize and characterize the vascular environment of the embryo.
08:24
Introduction to the Ultrasound Targeted Microbubble Destruction Technique
0 Views •
Cited by 19 •
2011
Ultrasound Targeted Microbubble Destruction (UTMD) can be used to direct site-specific delivery of bioactive molecules, including therapeutic genes, to target organs accessible to ultrasound, such as the heart and liver1-6.
02:37
Ophthalmic Drug Delivery for Noninvasive Neuromodulation in a Mouse Model
0 Views •
2025
Source: Zhan, J., et al. Non-invasive Strategies for Chronic Manipulation of DREADD-controlled Neuronal Activity. J. Vis. Exp. (2019)This video demonstrates a non-invasive ophthalmic drug delivery method for targeted neuromodulation. The drug is delivered via eye drops, absorbed into the circulation, crosses the blood-brain barrier, and activates specific neuronal receptors.
05:53
Intraluminal Drug Delivery to the Mouse Arteriovenous Fistula Endothelium
0 Views •
Cited by 5 •
2016
After puncturing the aorta through the inferior vena cava (IVC) to create an aorto-caval fistula in the mouse, solution containing a drug is infused into the IVC via the same needle, followed by incubation. This method enables more robust drug delivery to the venous endothelium compared to the external route.
FAQs
Ultrasound changes microbubble behavior in two important ways: the bubbles can oscillate, or they can undergo cavitation. These motions generate local mechanical forces that influence nearby cell membranes and can make them more permeable. That increase in permeability helps therapeutic material cross the membrane near the ultrasound-exposed site, linking acoustic stimulation to localized delivery.
During ultrasound exposure, therapeutic agents may leave the microbubble surface or a surrounding carrier, rather than relying on only one release route. At the same time, bubble motion can increase local membrane permeability. These parallel mechanisms connect release from the delivery system with entry into nearby cells, supporting site-specific treatment when ultrasound is applied.
Spatial control comes from applying ultrasound where release or membrane effects are wanted, instead of exposing the entire body to the same delivery stimulus. This localization can concentrate therapeutic action at a selected site while potentially lowering systemic exposure and off-target effects. The approach therefore links physical targeting with a more localized treatment response.
Ultrasound provides the external trigger that activates microbubble motion and associated mechanical effects. Because it can be applied noninvasively and used to control delivery in real time, treatment can be directed toward a chosen region without requiring the delivery system itself to provide all spatial control. This makes acoustic exposure central to the method's bioengineering design.
A basic workflow pairs a therapeutic agent with gas-filled microspheres or a surrounding carrier, places that delivery system in the body, and applies ultrasound at the intended site. The acoustic exposure activates bubble oscillation or cavitation, which can promote local release and increase membrane permeability. This sequence connects cargo transport with ultrasound-controlled delivery.
The platform is not restricted to conventional drugs. Supported cargo types include drugs, genes, and other biomolecules, allowing the same ultrasound-responsive strategy to address different therapeutic needs. The relevant outcome is controlled delivery at a selected site, where increased membrane permeability and local release may help the transported material reach nearby cells.
Cancer treatment and vascular medicine are prominent application areas because both benefit from localized delivery and control over exposure. In these settings, ultrasound can provide a noninvasive way to activate microbubbles and regulate treatment in real time. The approach is therefore relevant when researchers seek therapeutic action at selected sites while potentially limiting systemic and off-target effects.